Drug · CHEMBL1489
AZACITIDINE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. AZACITIDINE. Drugs and targets, record CHEMBL1489. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1489
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
- Azacitidine accord, Azacitidine betapharm, Azacitidine celgene, Azacitidine kabi, Azacitidine mylan, Onureg, Vidaza
- ChEMBL
- Open Targets' highest stage
- Approval, for 5 of its 100 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| DNMT1 | DNA (cytosine-5)-methyltransferase 1 | DNA (cytosine-5)-methyltransferase 1 inhibitor | INHIBITOR | https://conductscience.org/library/genes/1786 |
| DNMT3A | DNA (cytosine-5)-methyltransferase 3A | DNA (cytosine-5)-methyltransferase 3A inhibitor | INHIBITOR | https://conductscience.org/library/genes/1788 |
Source ChEMBL
Diseases100
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| acute myeloid leukemia | Approval | EMA Human Drugs | 448 | 441 | https://conductscience.org/library/drugs?q=MONDO_0018874 |
| myelodysplastic syndrome | Approval | DailyMed, EMA Human Drugs, PMDA and TTD | 299 | 285 | https://conductscience.org/library/drugs?q=MONDO_0018881 |
| chronic myelomonocytic leukemia | Approval | DailyMed and EMA Human Drugs | 71 | 60 | https://conductscience.org/library/drugs?q=MONDO_0020311 |
| mature T-cell and NK-cell non-Hodgkin lymphoma | Phase 3 | ClinicalTrials.gov | 18 | 18 | https://conductscience.org/library/drugs?q=MONDO_0000430 |
| leukemia | Phase 2 | ClinicalTrials.gov | 15 | 15 | https://conductscience.org/library/drugs?q=MONDO_0005059 |
| non-small cell lung carcinoma | Phase 2 | ClinicalTrials.gov | 15 | 15 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| acute lymphoblastic leukemia | Phase 2 | ClinicalTrials.gov | 14 | 14 | https://conductscience.org/library/drugs?q=MONDO_0004967 |
| diffuse large B-cell lymphoma | Phase 3 | ClinicalTrials.gov | 13 | 12 | https://conductscience.org/library/drugs?q=MONDO_0018905 |
| myeloproliferative disorder | Phase 2 | ClinicalTrials.gov | 11 | 11 | https://conductscience.org/library/drugs?q=EFO_0004251 |
| non-Hodgkin lymphoma | Phase 2 | ClinicalTrials.gov | 11 | 11 | https://conductscience.org/library/drugs?q=MONDO_0018908 |
1 to 10 of 100Source Open Targets
See all 100 diseasesTrials737
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 8 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 54 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03416179 | A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia | Phase 3 | 730 | 2021-06-25 | azacitidine | Its name | ClinicalTrials.gov |
| NCT04313881 | Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) | Phase 3 | 539 | 2024-03-21 | azacitidine | Its name | ClinicalTrials.gov |
| NCT04266301 | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) | Phase 3 | 530 | 2025-12-12 | azacitidine | Its name | ClinicalTrials.gov |
| NCT01074047 | Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) | Phase 3 | 488 | 2015-02-26 | azacitidine | Its name | ClinicalTrials.gov |
| NCT01757535 | Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission | Phase 3 | 472 | 2020-11-06 | azacitidine | Its name | ClinicalTrials.gov |
| NCT03268954 | Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) | Phase 3 | 454 | 2022-09-22 | azacitidine | Its name | ClinicalTrials.gov |
| NCT02993523 | A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy | Phase 3 | 443 | 2023-01-27 | azacitidine | Its name | ClinicalTrials.gov |
| NCT05079230 | Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia | Phase 3 | 378 | 2025-04-04 | azacitidine | Its name | ClinicalTrials.gov |
| NCT02421939 | A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | Phase 3 | 371 | 2019-10-17 | azacitidine | Its name | ClinicalTrials.gov |
| NCT00071799 | A Survival Study in Patients With High Risk Myelodysplastic Syndromes Comparing Azacitidine Versus Conventional Care | Phase 3 | 358 | 2010-07-05 | azacitidine | Its name | ClinicalTrials.gov |
1 to 10 of 737
See all 737 trialsComparisons in its trials144
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Magrolimab + Azacitidine vs Placebo + Azacitidine: deaths from any cause | 145 of 268 | 132 of 271 | 539 | NCT04313881 | Trial comparisons |
| Sabatolimab (MBG453) + Azacitidine vs Placebo + Azacitidine: deaths from any cause | 161 of 265 | 160 of 265 | 530 | NCT04266301 | Trial comparisons |
| Sabatolimab (MBG453) + Azacitidine vs Placebo + Azacitidine: serious adverse events | 174 of 263 | 164 of 265 | 528 | NCT04266301 | Trial comparisons |
| Magrolimab + Azacitidine vs Placebo + Azacitidine: serious adverse events | 189 of 263 | 136 of 264 | 527 | NCT04313881 | Trial comparisons |
| Azacitidine (AZA) vs Conventional Care Regimens (CCR): Number of Participants Who Achieved a Cytogenetic Complete Response (CRc-10) as Determined by the IRC. | 5 of 241 | 15 of 247 | 488 | NCT01074047 | Trial comparisons |
| Oral Azacitidine Plus Best Supportive Care vs Placebo Plus Best Supportive Care: deaths from any cause | 172 of 238 | 176 of 234 | 472 | NCT01757535 | Trial comparisons |
| Oral Azacitidine Plus Best Supportive Care vs Placebo Plus Best Supportive Care: serious adverse events | 110 of 236 | 109 of 233 | 469 | NCT01757535 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Number of Participants With at Least 1 Inpatient Hospital Admissions Related to HR MDS, CMML or Low-blast AML | 3 of 227 | 9 of 227 | 454 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Sixty-Day Mortality Reported as Number of Participants Who Died Up to Day 60 | 15 of 220 | 14 of 223 | 443 | NCT03268954 | Trial comparisons |
| Azacitidine 75 mg/m^2 vs Pevonedistat 20 mg/m^2 + Azacitidine 75 mg/m^2: Thirty-Day Mortality Reported as Number of Participants Who Died Up to Day 30 | 6 of 220 | 5 of 223 | 443 | NCT03268954 | Trial comparisons |
1 to 10 of 144
See all 144 comparisons in its trialsPapers from its trials245
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials1
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome |
|---|---|---|
| Go/No-Go Task | 1 | 1 |
Source ConductCognition
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1489
GET https://conductscience.org/api/drugs/v1/CHEMBL1489/diseases?page=2